The effect of atorvastatin on the treatment of secondary pulmonary hypertensio
Phase 2
- Conditions
- secondary pulmonary hypertension.Chronic lower respiratory diseasesJ40-J47
- Registration Number
- IRCT201108257411N1
- Lead Sponsor
- Tehran university of medical sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Systolic pulmonary hypertension>40mmhg; age 18 years or over until 80; no drug history of prostanoids, statins, endothelin antagonists and phosphodiesterase; able to doing 6-min walk test; obstructive pattern in PFT and functional class 2,3 (NYHA). Exclusion criteria: PAH from a cause other COPD; LDL<70 mg/dl; ALT or AST> 3x ULN.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Systolic pulmonary hypertension. Timepoint: At the beginning of study and 6 months later. Method of measurement: Echocardiography.
- Secondary Outcome Measures
Name Time Method CRP. Timepoint: At the beginning of study and 6 months later. Method of measurement: Lab data.;Cardiac output. Timepoint: At the beginning of study and 6 months later. Method of measurement: Echocardiography.;Right ventricular size. Timepoint: At the beginning of study and 6 months later. Method of measurement: Echocardiography.;6 min walk test. Timepoint: At the beginning of study and 6 months later. Method of measurement: By researcher.;FEV1, FVC, FEV1/FVC. Timepoint: At the beginning of study and 6 months later. Method of measurement: Spirometry.;Adverse effect of drug. Timepoint: One month after beginning and the end of treatment. Method of measurement: By lab data and symptoms.